International Justice Mission is a global organization that protects people in poverty from violence. IJM partners with local authorities in 21 program offices in 13 countries to combat slavery, violence against women and children, and other forms of abuse against people who are poor. IJM works to rescue and restore victims, hold perpetrators accountable, and help strengthen public justice systems. Learn more at IJM.org.IJM’s work has been recognized by the U.S. State Department, the World Economic Forum and leaders around the globe, as well as featured by The Guardian, The New York Times, Reuters, BBC and CNN, among many others.

nVent (NYSE: NVT) is an April 30, 2018 spin out from Pentair plc. It designs, manufactures, markets, installs, and services high performance electrical products and solutions that connect and protect some of the world's most sensitive equipment, buildings, and critical processes. The company offers a comprehensive range of enclosures, electrical connections and fastening, and thermal management solutions serving industrial, commercial/residential, infrastructure and energy customers. Executive officer responsible for Finance, IT, M&A and Business Transformation & Analytics. Scope: ~ $2.1B global revenue serving a $60B industry; operating domestically and internationally with over 50 sales offices and over 30 manufacturing and distribution centers across North America, Europe, Asia, Australia, and South America; ~ 9000 employees.* Directed separation activities in partnership with Pentair plc executives to establish two independent publicly traded companies.* Established capital structure and deployment strategy, investor relations and independent financial and IT operations for new company.* Initiated business transformation and data analytics capability in support of digital strategy and productivity goals.* Developed collaboration with activist shareholder and board director.* Navigated through complexities of US’ and other jurisdiction’s tax reforms and impact to the company’s inbound tax structure.* Drove annualized $35-40M cost reduction in response to softening business conditions.

Pentair plc (NYSE: PNR) has announced it will separate into two independent, publicly-traded companies in the second quarter of 2018. Today's Pentair Electrical will become tomorrow's nVent. nVent's mission is to connect and protect our customers with inventive electrical solutions, create safer systems and ensure a more secure world. As a high-performance electrical company, nVent is focused on improving utilization, lowering costs and maximizing customer uptime. nVent will employ approximately 9,000 people globally and recorded 2016 revenues of $2.1 billion. The new company will have industry-leading positions in industrial, commercial, residential, energy and infrastructure.

The Spectranetics Corporation (NASDAQ: SPNC) develops, manufactures, markets, and distributes single-use medical devices used in minimally invasive procedures in the cardiovascular system. Its products are used to cross, prepare, and treat arterial blockages in the legs and heart, and to remove pacemaker and defibrillator cardiac leads. Executive officer responsible for global finance and information technology functions. Scope: ~$300M global revenue serving $6.5B market, over 60 countries and 900 employees.• Expanded market value over 3X.• Initiated and directed investment, priority and timeline to build scale-able business processes to support transformative growth.• Led a 20% improvement in employee engagement scores (Willingness to Recommend).• Aligned internal and external resources for control structure and enterprise risk management improvement.• Upgraded talent and established new capabilities in treasury, forecasting, IR, analytics and accounting/reporting.• Directed legal entity architecture and tax strategy underpinning global expansion.• Improved insurance program value.• Raised $140M in covenant-light debt capital to fund growth strategy.

Senior business executive and corporate officer of MSA Safety Inc. (NYSE: MSA), a 100 year old publicly traded global safety company with sales into over 130 countries. Direct global finance and business development activities. Scope: $1.1B global revenue serving ~$12B addressable market, over 130 countries and 5,300 employees. • During tenure, MSA increased enterprise value over 18%, with enhanced strategic focus on margin expansion, inorganic growth and capital deployment. Co-led corporate strategy refresh exercise with quantified strategic targets and execution priorities for the company.• Established first global functional vision, strategy and measures of success across a highly fragmented, decentralized group of affiliates. Improved corporate finance engagement score by over 6%.• Created and resourced corporate treasury and investor relations functions. Debt restructure yielded lower financing costs and enhanced capacity and flexibility to support strategic growth and value creation initiatives. Initiated new capital deployment program to include executing a share repurchase element. Delivered expanded sell side coverage, attracted new investors, improved transparency, enhanced compliance with disclosure regulations and launched a new, user-friendly investor relations web site.• Established acquisition pipeline and prioritized assessment of targets against corporate strategic objectives, culminating in an acquisition of a priority target (not yet closed at the time of exit). Executed key divestitures of noncore businesses.

Direct global channel finance support function for research, safety and healthcare customers and suppliers with world class portfolio, customized solutions and global reach. Financial oversight of total company operations in India. Scope: Group oversight of two divisions and one business unit; $4.5 billion global revenue serving ~$25 billion market with 800,000 products and 6000 vendors. - Commercial Partnering - active engagement in delivering solutions to key customers and suppliers; governance of contracting and compliance; optimizing transaction structures.- Disciplined Cost Management - executed restructuring yielding $7 million annual savings; consolidated divisions to deliver improved customer experience and drive $4 million annual savings; oversight of $70 million ERP implementation and benefits realization in Europe.- Organization Effectiveness - founded first women's leadership group in company history, catalyzing Diversity & Inclusion program creation; introduced talent management and strategic communication plans within global finance team of over 300; aligned vision, strategic imperatives, tactics and metrics; introduced standardized processes to assess job levels, employee development and succession planning within group finance.

Expanded responsibilities to create value within enterprise-wide customer and logistics services as part of newly centralized supply chain organization. Scope: 250-300 distribution centers and hundreds of customer call centers servicing global economic customers of the J&J family of companies. Identified over $100MM in synergy opportunities in the first full year of operation. Designed accountability and monitoring systems to capture value.

Led 90-person finance and customer credit management function for shared service entity providing contract management, logistics and supply chain functions for the Johnson & Johnson family of companies. Also provides account management and customer support services to key commercial healthcare customers. Scope: $1.3B Accounts Receivable under management, $8.7B sales in distribution, $11B sales value in strategic accounts, $18B contracted sales under management.- Valued and assessed opportunity for operational efficiency gains across business (AR consolidation, distribution network optimization, transportation management, e-business leverage, conventions, commercial contracting, etc.). Delivered $60MM annual cash flow benefit over target from AR consolidation.- Controlled major enterprise projects (>$400MM investment value) to harmonize customer data, contract to cash business processes and supply chain integration. Delivered $200MM+ SAP project within approved scope and exceeded benefits.- Improved employee engagement by 57% over tenure.

Direct 80-person global Finance operations, U.S. Contract Administration and Sales Administration activities of $3.1B medical device company.• U.S. and World-wide Management Board member. Global resource allocation and portfolio management. J&J CFO leadership team.• Acting Interim President for 5 months during leadership turnover. Delivered and defended global Business Plan to MD&D Sector leaders. Defined and controlled major investment in field sales competitive defense. Risk management and process control of events leading up to Deferred Prosecution Agreement. Created process and discipline around price management, reversing declining price trends within 6 months. Led full revamp of royalty payment processes.• Instigated significant performance management initiative and talent upgrade in Warsaw finance division.

Directed 54-person U.S. finance team in financial reporting, compliance, manufacturing and commercial operations of a $1.3B domestic medical device company.• U.S. Management Board member responsible for designing and implementing new growth strategies under significant reorganization. Directed finance organization design and key communication to division.• Drove continuous improvement in key price erosion reserve methodology toward a controlled process and reduced volatility.• Exceeded Net Income targets in spite of dramatically lower sales.

Led 35-member team in finance, strategy and technology functions of $700M global animal health business.• Led valuation of business development deals for technology acquisition, third party manufacturing and commercial distribution agreements.• Directed strategic evaluation of business model and resulting restructuring project leading to major reorganization. • Established portfolio analysis capability influencing resource allocation and prioritization of $70 million R&D budget.

Member of startup phase executive team for first e.Lilly venture spinout, InnoCentive (http://www.innocentive.com).• Marketed novel internet-based R&D business model to life science companies. Within six months of business inception, recruited and realized revenues from Fortune 100 client.• Defined business model to attract equity partners; ePharmaceuticals' Top Story of 2001 in Pharmaceuticals/Products & Brands category.

Founding member of divisional senior management. Established $100 million e-business corporate venture capital capability. Division was awarded 2001 e-Business Innovator of the Year for outstanding contributions to the pharmaceutical industry.• Directed $50 million external corporate venture capital fund and $50 million internal venture risk capital fund. • Managed structuring and operational support of novel incubated firm matching technical problems to "solvers"; launched as InnoCentive. • Built divisional infrastructure: 20+ indirect team members; core business processes; internal and external communications; information technology support; finance and legal capabilities. Led creation of knowledge management tools and web site strategies.

Directed global IT project portfolio of $500M. Secretary to CIO Staff. • Re-engineered IT finance support to eliminate position; consolidated team within general and administrative finance support group.

Directed 23-person finance, IT, legal and business development functions for $130M pharmaceutical and animal health affiliate. Pension fund trustee. Australian Pharmaceutical Manufacturers' Association Finance Committee.• Established operational infrastructure for $12 million regional clinical data management center resulting from successful bid for government R&D incentive. Created strategy for late life cycle products and quadrupled affiliate profitability.• Board of Directors, Aza Research Pty Ltd. Designed and negotiated restructuring plan for $10 million endocrinology JV between Lilly Australia and Garvan Institute of Medical Research. • Implemented transfer pricing agreement with Australian tax office, $4 million estimated savings. Active voice in industry response to Australian Tax Reform proposal.• Established non-inventory procurement strategy, targeted savings $1 million. Introduced shared services across Australia and New Zealand, annual savings $300K.

Directed 13-person controllership team supporting marketing, manufacturing/export and regional home office for $630M affiliate. • Directed business development evaluation for emerging disease management and generics division.• Controller for two UK legal entities. Achieved 10% expense reduction targets. Directed management reporting data infrastructure strategy for progression to real-time views. Restructured to absorb 10% loss of human resources, maintaining service levels.

Led accelerated growth phase of specialty treasury affiliate, providing intra-group financial services.• Tripled assets under management to $1 Billion in two years with no increase in cost structure. Centralized cash management, decreased idle funds and surpassed EPS contribution by 30%.• Centralized and reduced global currency exposures. Rationalized intercompany transactions. Estimated annual savings $5 million.• Restructured intra-group netting and clearing processes, $500K annual transaction savings.• Developed and marketed intra-group treasury products per individual affiliate needs.

International Financial Analyst (Germany, UK, France, Italy), US Pharmaceutical Financial Analyst, Relief Sales Associate (Las Vegas, NV), Global Treasury Analyst